Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Although the epidermal growth factor receptor (EGFR) is overexpressed and/or amplified in more than 50 % of all glioblastomas (GBM), therapeutic targeting of the EGFR has not yet been successful. Since histone deacetylases (HDAC) have been described as controlling EGFR expression, we combined the EGFR tyrosine kinase inhibitor erlotinib with different HDAC inhibitors (HDACi) and investigated the benefit of combinatorial therapy for glioblastoma cells. Using representative models of EGFR-amplified, erlotinib-sensitive and -resistant GBM with or without EGFRvIII expression, we determined proliferation, migration, and EGFR-dependent signaling in response to erlotinib and HDACi alone or in combination. HDACi significantly inhibited proliferation of erlotinib-resistant GBM cells, partially restored their sensitivity to erlotinib, and also significantly reduced proliferation of all treatment-naïve cell lines tested. In combination with erlotinib, the development of resistance was prevented. The multitargeted EGFR/HDAC-inhibitor CUDC-101 exhibited similar effects. However, inhibition of cell migration was only achieved by targeting EGFR, and HDACi exhibited no additive effect. Mechanistically, we identified an HDACi-dependent decrease of EGFR/EGFRvIII protein expression underlying the anti-proliferative effects of HDACi. In conclusion, HDACi in combination with erlotinib might serve as a treatment option for newly diagnosed, treatment-naïve tumors irrespective of their EGFR status, as well as for treatment-refractory, EGFR-overexpressing GBM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while another HDAC inhibitor CUDC-101 has been found to enhance mut-p53 degradation leading to sensitization GBM cells to small molecule inhibitors of EGFR [140].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [140]
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2014) · Science · doi:10.1126/science.1241328 · Cited by 695
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Cited by
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
“Furthermore, HDAC inhibitor CCNU has been shown to sensitize adult GBM to chemotherapy with lomustine via degradation of mut-p53 [139], while another HDAC inhibitor CUDC-101 has been found to enhance mut-p53 degradation leading to sensitization GBM cells to small molecule inhibitors of EGFR [140].”
BackgroundEGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Westphal, M., Maire, C. L., & Lamszus, K. (2017) · CNS Drugs · doi:10.1007/s40263-017-0456-6 · Cited by 221
“The expression of the mutant EGFRvIII is also under tight control by epigenetic mechanisms as the inhibition of histone deacetylation resulted in reduction of EGFRvIII expression, which is thought to explain the relatively low and sparse EGFRvIII expression in tumor regions with high EGFR amplification and rearrangeme…”
BackgroundSelf-citationJenke, R., Reßing, N., Hansen, F. K., Aigner, A., & Büch, T. (2021) · Cancers · doi:10.3390/cancers13040634 · Cited by 180
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., de Álava, E., Hajji, N., & García-Domínguez, D. J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578011 · Cited by 177
Metadata
- Authors
- Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Schulte, Alexander
- Venue
- Targeted Oncology
- Published
- 2015-06-03
- Volume
- 11
- Issue
- 1
- Pages
- 29-40
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- OpenAlex
- W562420810
- Cited by
- 41
- References
- 47
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 6 · 2015: 3
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Targeted Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- histone deacetylase inhibitors, erlotinib, EGFR, EGFRvIII, glioblastoma, drug resistance, tyrosine kinase inhibitors, combination therapy, CUDC-101, cell proliferation, cell migration
- MeSH terms
- Erlotinib Hydrochloride, Cell Movement, Glioblastoma, Humans, RNA, Messenger, Tumor Cells, Cultured, Blotting, Western, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Protein Kinase Inhibitors, Cell Proliferation, Histone Deacetylase Inhibitors, Real-Time Polymerase Chain Reaction, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. https://app.cochat.ai/papers/10.1007/s11523-015-0372-y
- The paper
- Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A. (2016). Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. Targeted Oncology. https://doi.org/10.1007/s11523-015-0372-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.